Integrated and dual-responsive lipopeptide nanovector with parallel effect to tumor and micro-environment regulation by efficient gene and drug co-delivery

The integrated lipopeptide(RVA)/gene complexes are fabricated with bi-directional regulation on tumor cells and micro-environment.After self-assembling and target coating modification,the poly(γ-glutamic acid)(γ-PGA)/RVA nano-vectors can sequentially respond to pH&redox stimuli,and guarantee efficient therapeutic gene delivery and control release of all-trans retinoic acid.The design provides a facile but promising strategy to treat refractory cancers.

CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment

Clinical sorafenib treatment could activate C-X-C receptor type 4(CXCR4)/stromal source factor-1α(SDF-1α)axis to aggravate intra-tumoral hypoxia of hepatocellular carcinoma(HCC),which further leads to progression,invasion,metastasis,and immunosuppression of tumors and in return causes resistance to sorafenib therapy.Therefore,a multi-functional oxygen delivery nanoplatform was rationally constructed based on an oxygen-saturated perfluorohexane(PFH)-cored liposome,with the CXCR4 antagonist LFC131 peptides modifying on the surface to simultaneously deliver sorafenib and the CSF1/CSF1R inhibitor PLX3397(named PFH@LSLP)for sorafenib-resistant HCC treatment.The PFH@LSLP was developed to overcome sorafenib resistance by syner-gistic effects of the following 3 roles:1)the O_(2)-saturated PFH core could alleviate the tumor hypoxia by O_(2) supply;2)the LFC131 peptide recognized the hypoxia-related overexpressed CXCR4 and then blocked SDF-1α/CXCR4 axis to re-sensitize the HCC cells to sorafenib;3)PLX3397 activated the immune responses via inhibiting the CSF1/CSF1R pathway in TAMs,further enhanced CD8^(+)T cell infiltration to reverse immunosuppression in tumors.Antitumor performance on H22 tumor-bearing mice and HCC patient-derived tumor xenograft(PDX)model showed that PFH@LSLP could overcome sorafenib resistance by synergistic effect of hypoxia attenuation,resistance-related gene regulation,and immune-microenvironment modification.

Inhibition Mechanism of Qingluo Tongbi Granule(清络通痹颗粒)on Osteoclast Differentiation Induced by Synovial Fibroblast and Monocytes Co-Culture in Adjuvant-Induced Arthritic Rats

Objective： To study the mechanism underlying the inhibitory effect of Qingluo Tongbi Granule （清络通痹颗粒, QTG） on osteoclast differentiation in rheumatoid arthritis in rats. Methods： Fibroblast and monocyte co-culture were used to induce osteoclast differentiation in adjuvant-induced arthritic （AIA） rats. Serum containing QTG was prepared and added to the osteoclasts, and activation of the tumor necrosis factor receptorassociated factor 6/mitogen-activated protein kinase/nuclear factor of activated T cells, cytoplasmic1 （TRAF6/ MAPK/NFATcl） pathways was examined. Results： The induced osteoclasts were multinucleated and stained positive for tartrate-resistant acid phosphatase （TRAP） staining. Serum containing QTG at 14.4, 7.2 or 3.6 g/kg inhibited the activation of TRAF6, extracellular regulated protein kinase （ERK）1/2, c-Jun N-terminal kinase （JNK） and p38 and decreased the percentage of cells with nuclear NFATcl in a dose-dependent manner, the high and middle doses exhibited clear inhibitory activity （P〈0.01 and P〈0.05, respectively）. After the addition of MAPK inhibitors, the NFATcl expression showed no significant difference compared with the control group （P〉0.05）. Conclusions： Serum containing QTG could generally inhibit the TRAF6/MAPK pathways and possibly inhibit the NFATcl pathway. In addition, QTG may regulate other signaling pathways that are related to osteoclast differentiation and maturation.